LEXICON PHARMACEUTICALS INC. overview

Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences? PR Newswire NEW YORK, March 13, 2024 NEW YORK , March 13, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LXRX, SAVA, CLSD, LTRN, and ATAI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. LXRX:...

Thinking about buying stock in Comtech Telecommunications, Tantech Holdings, MDxHealth, Lexicon Pharmaceuticals, or micromobility.com? PR Newswire NEW YORK, Oct. 13, 2023 NEW YORK , Oct. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CMTL, TANH, MDXH, LXRX, and MCOM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CMTL:...

Thinking about buying stock in Immunic, BioXcel Therapeutics, Coherent Corp, Emx Royalty, or Lexicon Pharmaceuticals? PR Newswire NEW YORK, Oct. 10, 2023 NEW YORK , Oct. 10, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMUX, BTAI, COHR, EMX, and LXRX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. IMUX:...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX PR Newswire NEW YORK, March 26, 2022 NEW YORK , March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (NASDAQ: LXRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Lexicon and...

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX ) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Lexicon investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you...

Law Offices of Howard G. Smith announces an investigation on behalf of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX ) investors concerning the Company’s possible violations of federal securities laws. On February 28, 2022, Lexicon issued a press release announcing the voluntary withdrawal of the Company’s New Drug Application for its glucose regulation drug, sotagliflozin, in order to correct a technical issue with the submission that had been recently...

The Law Offices of Frank R. Cruz announces an investigation of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX ) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 28, 2022, Lexicon issued a press release announcing the voluntary withdrawal of the Company’s New Drug Application for its glucose regulation drug, sotagliflozin, in...